1208082-91-0

Basic information

• Product Name: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine
• Synonyms: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine
• CAS NO: 1208082-91-0
• Molecular Formula: C₇H₅Br₂N₃
• Molecular Weight: 290.9427
• Mol File: 1208082-91-0.mol

Chemical Properties

• Appearance: /
• Density: 2.19±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.66±0.30(Predicted)
• CAS DataBase Reference: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine(1208082-91-0)
• EPA Substance Registry System: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine(1208082-91-0)

Safety Data

• Hazardous Substances Data: 1208082-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its role in this industry is pivotal in creating new drugs and enhancing the efficacy of existing ones, contributing to the development of novel therapeutic agents.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine serves as an intermediate in the production of various agrochemicals. It aids in the formulation of pesticides, herbicides, and other agricultural chemicals that are essential for crop protection and increased agricultural productivity.

Upstream product

• 78-95-5 chloroacetone 
• 24241-18-7 2-amino-3,5-dibromopyrazine 

Downstream Products

• 1239717-63-5 C₁₇H₁₄BrN₅O 
• 1252594-72-1 3-(2-methyl-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)phenol 

Relevant articles and documents

Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS

There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS

The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.